[1] Mariani G, Bodei L, Adelstein SJ, et al. Emerging roles for radiometabolic therapy of tumors based on auger electron emission[J]. J Nucl Med, 2000, 41(9):1519-1521.
[2] Partensky C, Sassolas G, Henry L, et al. Intra-arterial iodine 131-labeled lipiodol as adjuvant therapy after curative liver resection for hepatocellular carcinoma:a phase 2 clinical study[J]. Arch Surg, 2000, 135(11):1298-1300.
[3] Larsen SW, Rinvar E, Svendsen O, et al. Determination of the disappearance rate of iodine-125 labelled oils from the injection site after intramuscular and subcutaneous administration to pigs[J]. Int J Pharm, 2001, 230(1):67-75.
[4] Blasco JC. Brachytherapy[J]. Urology, 2000, 55(2):306-308.
[5] Boland A, Ricard M, Opolon P, et al. Adenovirus-mediated transfer of the thyroid sodium/iodide symporter gene into tumors for a targeted radiotherapy[J]. Cancer Res, 2000,60(13):3484-3492.
[6] Krishnamurthy GT, Swailem FM, Swailem SC, et al. Tin117(4+)DTPA:Pharmacokinetics and imaging characteristics in patients with metastatic bone pain[J]. J Nucl Med,1997, 38(2):230-235.
[7] Goddu SM, Bishayee A, Bouchet LG, et al. Marrow toxicity of 33P-versus 32P-orthophosphate:implications for therapy of bone pain and bone metastases[J]. J Nucl Med, 2000, 41(5):941-951.
[8] Makhija S, Howden N, Edwards R, et al. Positron emission tomography/computed tomography imaging for the detection of recurrent ovarian and fallopian tube carcinoma:a retrospective review[J]. Gynecol oncol, 2002, 85(1):53-58.
[9] Yu JF, Yin DZ, Min XF, et al.(188Re)Rhenuim sulfide suspensio n:a potential radiopharmaceutical for treatment folowing intratumor injection[J]. Nucl Med Biol, 1999, 26:(5) 573-579.
[10] Nijsen F, Rook D, Brandt C, et al. Targeting of liver tumor in rats by selective delivery of holmium-166 loaded microsphers:a biodistribution study[J]. J Eur Nucl Med, 2001,28(6):743-749.
[11] Jacobs A, Tjuvajev JG, Dubrovin M, et al. Positron emission tomography-based imaging of transgene expression mediated by replication-conditional, oncolytic herpes simplex virus type 1 mutant vectors in vivo[J]. Cancer Res,2001, 61(7):2983-2995.
[12] de Jong M, Breeman WAP, Bernard WA, et al.[177LuDOTA0, Tyr3] octreotate for somatostatin receptor-targeted radionuclide therapy[J]. Int J Cancer, 2001, 92(5):628-633.
[13] Eisenwiener KP, Prata MI, Buschmann I, et al. NODAGATOC, a new chelator-coupled somatostatin analogue labeled with[67Ga/68Ga] and 111In for SPECT, PET, and targeted therapeutic applications of somatostatin receptor(hsst2)expressing tumors[J]. Bioconjug Chem, 2002,13(3):530-541.
[14] Janson ET, Westlin JE, Ohrvall U, et al. Nuclear localization of 111In after intravenous injection of [111In-DTPA-DPhe1]-octreotide in patients with neuroendocrine tumors[J].J Nucl Med, 2000, 41(9):1514-1518.